Advanced Filters
noise

Additional Locations, New York Clinical Trials

A listing of Additional Locations, New York clinical trials actively recruiting patient volunteers.

Found 2,810 clinical trials
C Cancer Clinical Trials Team

Amping up With PemJAK

The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.

18 - 95 years of age All Phase 2
M Matthew Amsden

Evaluating Heart & Soil's Whole Package on Men's Health

This study explores how Heart \& Soil's Whole Package impacts men's hormone health, strength, and virility using blood testosterone tracking and self-reported measures.

18 years of age Male Phase N/A
G Grace Ha

Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)

The study is a prospective, single-arm, pre-market clinical study and will enroll up to 300 subjects at up to 26 sites in the United States (US) for analysis of primary objectives. No single site may contribute more than 15% of the enrollments.

18 - 80 years of age All Phase N/A

The CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction

This clinical trial evaluates the VapeAway system, a novel, multi-modal intervention designed to address the multifaceted nature of vaping addiction. VapeAway combines progressive nicotine tapering via proprietary filters, behavioral substitution with a sensory device (Fix Bar), and structured digital support. The purpose of this research is to evaluate the efficacy …

21 years of age All Phase 2

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people who have localized high-risk prostate cancer.

18 years of age All Phase 2
U Urvi A Shah, MD, MS

A Dietary Study for People With Multiple Myeloma

The purpose of the study is to find out whether a dietary intervention can affect treatment response and/or quality of life for people with newly diagnosed multiple myeloma receiving standard induction chemotherapy with daratumumab (or isatuximab), lenalidomide, bortezomib, and dexamethasone (DRVd). The researchers will measure quality of life by having …

18 years of age All Phase N/A
O Orson Xu, Ph.D.

Cognitive Training for Student Sleep and Wellness

This randomized control trial (RCT) explores two potential stress reduction interventions: a digital mindfulness program personalized for first year college students and a problem-solving based stress management program. These interventions were chosen because they rely on evidence-based approaches to stress management: problem-solving for cognitive coping and mindfulness for attention monitoring …

18 years of age All Phase N/A

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study of NEO-811 for subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monotherapy.

18 years of age All Phase 1

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.

18 - 70 years of age All Phase 2
C Chrisanna Dobrowolski, MD

Alnuctamab for Refractory SLE (LATTE Study)

This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate to severe SLE, refractory to standard-of-care treatments.

18 - 60 years of age All Phase 1

Simplify language using AI